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Abstract
Background: The management of schizophrenia is evolving towards a more comprehensive model based on
functional recovery. The concept of functional recovery goes beyond clinical remission and encompasses multiple
aspects of the patient’s life, making it difficult to settle on a definition and to develop reliable assessment criteria.
In this consensus process based on a panel of experts in schizophrenia, we aimed to provide useful insights on
functional recovery and its involvement in clinical practice and clinical research.
Methods: After a literature review of functional recovery in schizophrenia, a scientific committee of 8 members
prepared a 75-item questionnaire, including 6 sections: (I) the concept of functional recovery (9 items), (II) assessment
of functional recovery (23 items), (III) factors influencing functional recovery (16 items), (IV) psychosocial interventions
and functional recovery (8 items), (V) pharmacological treatment and functional recovery (14 items), and (VI)
the perspective of patients and their relatives on functional recovery (5 items). The questionnaire was sent to
a panel of 53 experts, who rated each item on a 9-point Likert scale. Consensus was achieved in a 2-round
Delphi dynamics, using the median (interquartile range) scores to consider consensus in either agreement
(scores 7–9) or disagreement (scores 1–3). Items not achieving consensus in the first round were sent back
to the experts for a second consideration.
Results: After the two recursive rounds, consensus was achieved in 64 items (85.3%): 61 items (81.3%) in agreement and
3 (4.0%) in disagreement, all of them from section II (assessment of functional recovery). Items not reaching consensus
were related to the concepts of functional recovery (1 item, 1.3%), functional assessment (5 items, 6.7%), factors influencing
functional recovery (3 items, 4.0%), and psychosocial interventions (2 items, 5.6%).
Conclusions: Despite the lack of a well-defined concept of functional recovery, we identified a trend towards a common
archetype of the definition and factors associated with functional recovery, as well as its applicability in clinical practice and
clinical research.
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Background
The management of schizophrenia has traditionally
focused on the assessment of symptomatology and
neurocognitive functioning [1]. However, there is in-
creasing interest in developing more comprehensive
models focusing on functional recovery [2–9]. Unlike
clinical remission, which is well defined and can be
measured, the concept of recovery encompasses mul-
tiple aspects of the patient’s life, making it difficult to
settle on a definition and to develop reliable assess-
ment criteria. Liberman and colleagues [10] proposed
operational criteria for recovery from schizophrenia
that included symptom remission, improved voca-
tional functioning, independent living, and improved
peer relationships. In contrast, Anthony [11]
described functional recovery as a deeply personal,
unique process of changing one’s attitudes, values,
feelings, goals, skills, and/or roles, even with limita-
tions caused by illness. On the other hand, some cli-
nicians have warned that functional recovery can only
be accepted when symptoms are mild and stable
enough to not interfere with normal functioning in
social activities and relationships [6, 12]. Regardless of
the perspective of the various stakeholders, it is
widely accepted that functional recovery is influenced
by the severity of symptoms as well as by
disease-related aspects such as neurocognitive per-
formance [7, 13–15]. Additionally, social and family
circumstances, opportunities, and lifetime events con-
tribute to extending the list of environmental factors
that may influence functional recovery beyond clinical
manifestations of schizophrenia [7, 15, 16].
Patients with schizophrenia now have access to a wide
variety of pharmacological agents and psychosocial ther-
apies which may eventually meet the particular needs of
each patient profile and, therefore, increase the chances
of positive therapeutic outcomes [17]. The lack of stan-
dardized tools for the assessment of functional recovery
prevents from drawing strong conclusions regarding the
contribution of these interventions to functional recov-
ery in patients with schizophrenia. Nevertheless, results
of clinical studies – including randomized controlled tri-
als – on various interventions for schizophrenia suggest
that the achievement of functional recovery is possible
in many cases [18–21].
Due to the heterogeneity of published information
and the limited empirical evidence on functional re-
covery, this concept is not commonly considered an
assessment criterion and/or a therapeutic goal in
most clinical practice guidelines [1]. In a
non-standardized way, most clinicians are familiar
with the concept of functional recovery and consider
it useful in their day-to-day practice [22]. Neverthe-
less, it is not clear whether clinicians have a common
construct of functional recovery and to what extent
these ideas meet the empirical evidence published in
the literature. We present herein the results of a Del-
phi consensus process aimed to identify commonly
accepted concepts regarding the definition and assess-
ment of functional recovery, as well as the perceived
impact of psychosocial and pharmacological interven-
tions on its attainment.
Methods
Design of the consensus dynamics
The aim of this consensus was to apprise various aspects
related to the assessment and functional intervention of
patients with schizophrenia and provide clinicians and
investigators with insights into functional recovery in
patients with schizophrenia. The consensus process was
approached through two recursive rounds of Delphi
dynamics. The Delphi methodology is a structured, sys-
tematic, and interactive forecasting method based on the
individual judgments of a panel of experts [23, 24]. The
two Delphi rounds were held between May 5th 2016 and
July 1st 2016. In each round, experts anonymously
acceded to an online questionnaire and rated each item
in the questionnaire on a 9-point Likert scale, where
lower scores meant disagreement and higher scores
meant agreement. For each item, consensus was consid-
ered when at least two-thirds of the experts scored
either 1-to-3 (disagree) or 7-to-9 (agree) (Additional file 1:
Table S1). Conversely, non-consensus was considered
when the interquartile range (i.e. percentiles 25–75) was
greater than 4 or when one-third of the experts or more
scored either 1-to-3 or 7-to-9. In that case an indeter-
minate level was assigned to items not meeting the
criteria for either consensus or non-consensus. Items
not achieving consensus in the first round were sent
back to the experts for a second assessment round.
Using bar graphs, a research assistance team, which
did not interfere in the responses, assessed and pre-
sented the results from the first round to facilitate com-
ments and clarifications from each participant. In the
second round, the expert panelists contrasted their per-
sonal opinion with the result of the first round and, if
necessary, reconsidered their initial opinion on those
items in which consensus was not reached. The results
of this second round were tabulated and presented de-
scriptively using the median and interquartile range and
the percentage of experts agreeing/disagreeing a particu-
lar statement.
At the end of the Delphi process, the scientific commit-
tee discussed the final results during a group session, held
on October 15th, 2016. A manuscript was drafted with
the conclusions drawn from the responses of the panel of
experts and the literature review, which was revised and
approved by all members of the scientific committee.
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Participants
The scientific committee consisted of eight psychiatrists
from Spanish hospitals. Each member of the scientific
committee proposed and recruited psychiatrists from
Spanish hospitals, outpatient units, and academic set-
tings to participate in the panel of experts. To be
included in the panel, the expert must have at least
10 years of experience in a hospital setting. To prevent
attrition bias between the two rounds, only experts who
completed the entire Delphi process were to be listed in
the acknowledgement section of the publication [25].
The research assistance team, led by BH, directed and
oversaw the entire process and was responsible for the
distribution and analysis of the questionnaires.
The questionnaire
After a literature review of the empirical evidence and ex-
pert opinions on functional recovery in patients with
schizophrenia, the members of the scientific committee
discussed the unmet needs regarding the definition of
functional recovery and its assessment, as well as the pos-
sible interventions to accomplish it. The items of interest
were summarized in a questionnaire of 75 items, which
were grouped into six sections: (I) the concept of func-
tional recovery (9 items), (II) assessment of functional
recovery (23 items), (III) factors influencing functional re-
covery (16 items), (IV) psychosocial interventions and
functional recovery (8 items), (V) pharmacological treat-
ment and functional recovery (14 items), and (VI) the per-
spective of patients and their relatives on functional
recovery (5 items). The questionnaire was sent to the
experts in the panel for their consideration.
Results
Consensus overview
Based on the criteria of the members of the scientific
committee, 80 experts were invited to participate in the
Delphi process. Of them, 53 responded the first round
and 53 in the second one, indicating no drop out be-
tween the two recursive rounds of the Delphi process. In
the first round, consensus was achieved in 41 items
(54.7%), all of them in agreement. Of the 34 items
addressed in the second round, 23 met the consensus
criteria (20 items in agreement and 3 in disagreement),
yielding a final consensus list of64 items (85.3%): 61
(81.3%) in agreement and 3 (4.0%) in disagreement.
Table 1 shows the number and percentages of items in
each section on which the experts reached agreement
(i.e. consensus on the score range 7-to-9), disagreement
(i.e. consensus on the score range 1-to-3), and lack of
consensus. Of eleven items not meeting the consensus
criteria, one resulted in non-consensus (i.e. more than
one-third of experts scoring 1-to-3 and more than
one-third scoring 7-to-9) and ten were indeterminate
(i.e. not meeting criteria for either consensus or
non-consensus) (Fig. 1). Most items not reaching con-
sensus belonged to the functional assessment section
(5 items, 6.7%), followed by factors influencing func-
tional recovery (3 items, 4.0%), psychosocial interven-
tions and functional recovery (2 items, 5.6%), and the
concept of functional recovery (1 item, 1.3%).
Additional file 1: Tables S2-S7 provide details on the
median and interquartile range obtained on each
item. The median score in items meeting the consen-
sus criteria ranged from 6.06 to 8.31.
The concept of functional recovery
Additional file 1: Table S2 summarizes the median
scores of the 9 items regarding the concept of functional
recovery. The experts did not reach a consensus regard-
ing the existence of a standardized concept of functional
recovery in patients with schizophrenia (57.7% of agree-
ment; median score 7.06; 95%CI 6.50–7.50). Neverthe-
less, the experts in the panel overall agreed on each one
of the multiple characteristics frequently included in the
definition of functional recovery. For instance, most
Table 1 Consensus rate in each section of the questionnaire
No. %
I. The concept of functional recovery (n = 9)
Agreement 8 88.9%
Disagreement 0 –
No consensus 1 11.1%
II. Functional assessment (n = 22)
Agreement 15 68.2%
Disagreement 3 13.6%
No consensus 5 22.7%
III. Factors influencing functional recovery (n = 16)
Agreement 13 81.3%
Disagreement 0 –
No consensus 3 18.8%
IV. Psychosocial interventions and functional recovery (n = 8)
Agreement 6 75.0%
Disagreement 0 –
No consensus 2 25.0%
V. Functioning and pharmacological treatment (n = 14)
Agreement 14 100%
Disagreement 0 –
No consensus 0 –




No consensus 0 –
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experts agreed that functional recovery overlaps with other
concepts such as quality of life, cognition, and clinical remis-
sion. Furthermore, experts identified the influence of symp-
tomatic remission, personal autonomy, professional activity,
social relationships, and environmental factors on functional
recovery. According to 86.5% of the experts, functional re-
covery is an achievable goal in patients with schizophrenia.
Assessment of functional recovery
According to the experts, the assessment of functional re-
covery is essential in both the clinical research and clinical
practice settings (96.2% of consensus). However, there was
no consensus on whether the assessment of functional re-
covery is commonly included among study objectives of
clinical trials in schizophrenia (Additional file 1: Table S3).
Fig. 1 Results of the items not meeting the consensus criteria. a functional recovery is a well-established concept. b The functional assessment is
commonly included among the objectives of clinical trials on schizophrenia. c the patient is the most reliable source of information for
functional assessment. d: a proper functional assessment is not affordable in institutionalized patients. e I am familiar with the use of the
Social and Occupational Functioning Assessment Scale (SOFAS) regarding the functional assessment of schizophrenic patients. f I am familiar
with the use of the Health of the Nation Outcome Scales (HoNOS) regarding the functional assessment of schizophrenic patients. g living in
an urban area is the environmental factor that has the greatest impact on functioning in patients with schizophrenia. h being an immigrant is
the environmental factor that has the greatest impact on functioning in patients with schizophrenia. i: Public campaigns aimed at reducing
stigma in patients with schizophrenia are effective. j cognitive-behavioral therapy is the most effective psychosocial intervention for functional recovery.
k cognitive disorders should be the primary target of psychosocial interventions
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Regarding the source of information for the assessment of
functional recovery, there was strong agreement (98.1%) on
the suitability of gathering information from three primary
sources: patients, their relatives (and/or caregivers), and cli-
nicians. The experts exhibited heterogeneous knowledge of
the functional assessment tools currently available for iden-
tifying areas subject to improvement, and planning the
management of patients with schizophrenia. Most of them
stated that they were familiar with the GAF scale, the
Personal and Social Performance scale (PSP), and the sec-
ond version of the World Health Organization Disability
Assessment Schedule (WHODAS 2.0). Conversely, the ma-
jority of experts were not familiar with the Social and
Occupational Functioning Assessment Scale (SOFAS) or
the Health of the Nation Outcome Scale (HoNOS). Beyond
the scales used, it was suggested that functional recovery is
somehow assessed in routine practice, albeit without any
standardized procedure.
Factors influencing functional recovery
The experts overall agreed that functional recovery is in-
fluenced by various environmental factors, including
stressful life events, substance abuse, socioeconomic
conditions, and family dynamics (Additional file 1: Table
S4). However, most of them (90%) acknowledged that
none of these factors predicts independently the
non-achievement of functional recovery. Other environ-
mental factors such as the type of origin (i.e. migrant/
local) and residence (i.e. urban/rural) were not consid-
ered to influence functional recovery significantly. Both
negative and cognitive symptoms were considered to
cause significant impact on functional recovery, with no
superiority of either of the two symptom groups. Finally,
the experts agreed that self-stigma (or internalized
stigma) has a greater impact on functional recovery than
social stigma. The idea that the negative image associ-
ated with psychiatry compared to other medical special-
ties increases stigma in patients with schizophrenia also
reached a consensus in agreement.
Psychosocial interventions and functional recovery
There was overall agreement that psychosocial interven-
tions are necessary to achieve functional recovery (92.3%
of agreement). Among all interventions proposed, family
interventions and those aimed at developing social skills
and improving employability were considered the most
useful for functional recovery (Additional file 1: Table
S5). Although the inclusion of cognitive rehabilitation in
psychosocial interventions was considered useful, cogni-
tive disorders were not agreed to be the primary target
of these interventions.
Pharmacological treatment and functional recovery
The majority of experts in the panel (79.0%) considered
that functional recovery is one of the most important
criteria determining the choice of pharmacological treat-
ment (Additional file 1: Table S6). It was also agreed that
the various antipsychotic agents have different impacts
on functional recovery. Among the potential drawbacks
of pharmacological treatment for achieving functional
recovery, cognitive impairment reached the highest
agreement (100%); 94.3% of the experts agreed that
second-generation are more useful than first-generation
(or atypical) antipsychotics for achieving functional
recovery.
The perspective of patients and their relatives on
functional recovery
The experts agreed that the perspective of clinicians on
functional recovery differed significantly from that of
patients and their relatives (Additional file 1: Table S7).
According to this observation, psychiatrists are more
concerned with the clinical aspects of the disease,
whereas patients and their relatives are more concerned
with subjective aspects of the lifetime project and factors
influencing activities of daily living.
Discussion
Following a two-round Delphi dynamics approach, we
found high homogeneity in the opinion of clinicians
regarding functional recovery in patients with schizo-
phrenia. Psychiatrists from different areas in Spain
achieved consensus in 85% of the concepts addressed
regarding various aspects of functional recovery.
Functional recovery is a complex, multidimensional
concept to be considered not only by clinicians but also
researchers, patients and caregivers, as well mental
health policy makers. Although the perspective of the
various stakeholders involved in the definition of func-
tional recovery may converge on many aspects, the lack
of a common terminology and the pursuit of different
goals has led to a wide repertoire of definitions, none of
which stands out clearly over the rest [2, 6, 7, 16, 26].
The result of our consensus regarding the concept of
functional recovery mirrored this scenario, resulting in a
lack of consensus regarding a well-established concept
of functional recovery. Nevertheless, the general agree-
ment on specific factors influencing the concept of func-
tional recovery suggests that despite the lack of a
standardized definition of recovery, most clinicians share
a common archetype of what functional recovery
actually is.
The feasibility of achieving functional recovery in
patients with schizophrenia has been under discussion
since the emergence of interest in this concept [2, 6,
22, 27]. Most experts in our panel (87%) agreed that
functional recovery is a realistic goal in the manage-
ment of patients with schizophrenia. This is in line
with the results of recent research on schizophrenia,
Lahera et al. BMC Psychiatry  (2018) 18:176 Page 5 of 10
which showed that psychological well-being and mental
health recovery can improve in individuals with
first-episode psychosis [28]. The lack of a clear definition
and assessment tools prevents from drawing strong con-
clusions regarding the feasibility of a therapeutic model
based on the concept of recovery. However, empirical evi-
dence on various therapeutic interventions suggests that
many patients with schizophrenia can achieve goals
related to functional recovery such as independent living
and competitive employment and education in routine
community settings [18–21, 29]. In line with the common
perception regarding the definition of functional recovery,
M. Farkas proposed four key values commonly reflected
in the recovery literature which should be considered in
all recovery-oriented services: person orientation, person
involvement, self-determination/choice, and growth
potential [30].
The lack of a standardized definition is probably a
bottleneck for the development of validated tools for the
assessment of functional recovery. Other difficulties that
may compromise an appropriate assessment of functional
recovery include the limitations of some informants to
make accurate judgments [31], the limited capacity of
some patients for self-assessment [32], and the heterogen-
eity in their clinical course, which may lead to inconsisten-
cies between the outcome of functioning scales and
milestone achievement in some patients (e.g., in some
patients, functioning scales may not capture milestone
achievements in social, vocational, and residential
domains of patients with schizophrenia) [33]. Regarding
the source of information for the assessment of functional
recovery, there was strong agreement on the suitability of
gathering information from three primary sources:
patients, their relatives (and/or caregivers), and clinicians.
Indeed, some authors have warned of the risk of bias asso-
ciated with motivation-related negative symptoms (e.g.
emotional withdrawal, passive-apathetic social withdrawal)
[34]. Furthermore, patient-reported assessments of quality
of life and everyday abilities have shown poor correlation
with information about lifetime achievements in many
patients with schizophrenia [35]. All these limitations are
consistent with the lack of consensus on the concept that
the patient is the most reliable source of information for
functional assessment.
Due to the absence of a single tool for the assessment
of functional recovery, clinicians and researchers use dif-
ferent strategies to evaluate it. In an attempt to broaden
functional assessment towards a comprehensive model
of functional recovery, researchers have combined com-
monly used scales such as the Global Assessment Func-
tioning (GAF) scale and Global Assessment Scale (GAS)
with the Social Functioning Rating Score – which
includes both social skills and social roles – and other
objective indicators of lifetime achievements [36–38].
The experts exhibited heterogeneous knowledge of the
functional assessment tools currently available for identi-
fying areas subject to improvement, and planning the
management of patients with schizophrenia. Beyond the
scales used, it was suggested that functional recovery is
somehow assessed in routine practice, albeit without any
standardized procedure. In this regard, treatments based
on a recovery model should be consistent with
evidence-based treatments [2].
Functional recovery, may be influenced by multiple
factors. According to the experts, these factors are a
combination of environmental factors, stressful life
events, substance abuse, socioeconomic conditions,
and family dynamics. Other environmental factors
such as the type of origin (i.e. migrant/local) and resi-
dence (i.e. urban/rural) were not considered to influ-
ence functional recovery significantly. Some authors
have observed that patients living in rural areas tend
to show better functional outcomes, probably due to
greater family and social support as well as simpler
vocational roles [39]. However, in our consensus, the
experts’ opinion might be strongly influenced by the
area where they work. Thus, while some centers pro-
vide mental health care to patients from both rural
and urban areas, most of them serve one or the other
type, whereby the influence of this factor may be un-
noticed. Finally, there was 96% agreement that, des-
pite the different perspectives of clinicians and
patients (i.e. clinicians tend to focus on the clinical
aspects of recovery, whereas patients and their rela-
tives attach importance to the activities of daily living
and life project), the attitude of the various stake-
holders has an influence on functional recovery.
In line with the results of clinical studies, which sug-
gest that both negative symptoms and cognitive deficits
may be primary predictors of impaired social and voca-
tional performance [34, 40, 41], the experts in the panel
agreed that both negative and cognitive symptoms cause
a significant impact on functional recovery. Also, in
agreement with recent recommendations to treat nega-
tive symptoms [42], the experts agreed that functional
recovery should not be addressed only through symp-
toms but also considering the cognitive, emotional, and
relationship difficulties.
Stigma is another factor with potential influence on
functional recovery, and it is generally accepted that it
has a major impact on self-esteem and hampers recovery
in people with mental illnesses [7, 43]. The experts
agreed that the negative image associated with psych-
iatry compared to other medical specialties increases
stigma in patients with schizophrenia and that
self-stigma (or internalized stigma) has a greater impact
on functional recovery than social stigma. Although the
mechanisms of stigma are not clear, social (or public)
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stigma and self-stigma might work in different ways. In
an interview-based study conducted on patients with
major depression or schizophrenia, social stigma showed
a trend towards underestimating the importance of in-
formal caregivers (e.g. family and friends). Conversely,
self-stigma had a negative impact on the perceived im-
portance of seeking help provided by a general practi-
tioner or a psychiatrist [44].
The relevance of psychosocial interventions agreed in
this consensus are consistent with the positive results
of these interventions reported in randomized clinical
trials conducted according to the gold standards of
clinical design [45–47]. Although the items regarding
the type of therapy with highest effectivity were written
in an exclusive way, the experts achieved consensus in
the highest effectivity of social skills training, family
therapy, cognitive rehabilitation, social cognitive train-
ing, and occupational programs. This result indicates
that, irrespective of the median score achieved in each
therapy, none of them stood out from the rest. Of note,
recovery-based interventions are not widespread in
clinical practice and some authors have stressed the
need to develop more interventions going beyond
symptom reduction [48]. Although the inclusion of
cognitive rehabilitation in psychosocial interventions
was considered useful, cognitive disorders were not
agreed to be the primary target of these interventions.
The apparent inconsistency regarding the role of cogni-
tive functioning in psychosocial interventions can be
explained by the recent evolution of the concept of
cognition. Thus, while the construct of cognitive im-
pairment has been traditionally built solely on basic
neurocognition, it is now accepted that social cognition
differs from basic neurocognition and that it could be
the link between neurocognition and functional recov-
ery in psychosocial programming [5, 49].
The positive impact of long-acting antipsychotics on
adherence and the closer relationship between patients
and the healthcare team associated with the dosing of
these agents have been considered helpful for achieving
functional recovery [38]. Some authors have questioned
the suitability of maintaining long-lasting treatment with
antipsychotics [50]. However, the impact of long-lasting
antipsychotic treatments on functional recovery is
unclear, and other authors have highlighted important
limitations of studies investigating early discontinuation
of antipsychotic therapy [51].
Although it is not clear whether medication alone can
impact directly on functional performance, there is
long-time evidence on the synergistic effect of pharma-
cological and psychosocial treatments, particularly
pharmacological treatments with a significant impact on
positive symptoms [7, 52–54]. Besides attenuating
the symptomatology associated with schizophrenia,
pharmacological treatments – particularly atypical anti-
psychotic agents – cause morphological changes in pa-
tients’ brains which could be associated with an
improvement in neurochemical functioning [55, 56].
Despite the proven usefulness of some antipsychotic
agents in achieving functional recovery [57, 58], the
experts identified potential drawbacks of pharmaco-
logical treatment for achieving functional recovery:
extrapyramidal symptoms, sedation, the worsening of
negative symptoms, and cognitive impairment. Of note,
most of the adverse events limiting functional recovery
are more frequently associated with first-generation than
second-generation antipsychotics [59–61]. Combination
antipsychotic therapy was also considered to result in
poorer functional recovery than monotherapy.
Table 2 List of recommendations when addressing functional
recovery of patients with schizophrenia
The concept of functional recovery
Despite the lack of a unified definition of functional recovery, it is
recommended to ponder quality of life, cognition and clinical
remission when considering functional recovery in research and
routine practice.
Functional recovery should be considered a goal in the management
of patients with schizophrenia.
Functional recovery should be always included among endpoints of
clinical trials assessing patients with schizophrenia.
Assessment of functional recovery
Irrespective of the tools used for assessing functional recovery,
information for appraising it should be gathered from patients, their
relatives (and/or caregivers), and the healthcare team.
Irrespective of the tools used for assessing functional recovery, the
patient’s socio-cultural background should be considered when
assessing functional recovery.
Factors influencing functional recovery
When seeking for the achievement of functional recovery, the
combined influence of stressful life events, substance abuse,
socioeconomic conditions, and family relationships, should be
considered.
Although negative symptoms have a great impact on functioning,
clinicians should not focus exclusively on symptom remission when
considering functional recovery.
Psychosocial interventions and functional recovery
Psychosocial interventions are necessary to achieve functional
recovery. A combination of various therapies (including social skills
training, family therapy, cognitive rehabilitation, social cognitive
training, and occupational programs) is likely to be most useful in
achieving functional recovery.
Pharmacological treatment and functional recovery
Functional recovery should be considered in decision-making on
pharmacological treatments.
The perspective of patients and their relatives on functional recovery
The attitudes of all stakeholders (i.e., patients, their relatives, and
clinicians) influence functional recovery. Hence, when seeking for
achieving functional recovery, all these perspectives should be taken
into account.
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The scope of the results presented herein must be
weighed considering some limitations of our work. First, the
selection of experts was neither systematic nor randomized.
Alternatively, we recruited specialists in the management of
schizophrenia from various Spanish regions. Thus, although
all experts must account at least 10 years of clinical practice,
a selection bias cannot be ruled out. Second, some items ex-
pressing mutually incompatible ideas yielded inconsistent
results. Items affected by this phenomenon were discussed
and eventually not considered for drawing the final conclu-
sions. Finally, the resulting recommendations were not
drawn following a consensus process, but as an interpret-
ation of the agreements and disagreements resulting from
the Delphi process. Nevertheless, due to the expected
heterogeneity on the concept, we deemed it more appropri-
ate to address the conclusions by weighing the scope of
each result carefully and addressing the inconsistencies that
might arise from the responses of the panel of experts.
Conclusions
Despite the lack of a standardized definition of func-
tional recovery in schizophrenia, clinicians are aware of
this approach, show a trend towards a common con-
struct of this concept, and consider functional recovery
in their day-to-day practice, albeit in a non-formal way.
In our experience, 57 Spanish psychiatrists reached a
consensus on 85% of items addressing various aspects of
functional recovery in schizophrenia. Based on the
results of this consensus and their consistency with the
information available in the literature, the experts of this
panel provide a list of recommendations (Table 2).
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